TG Therapeutics Inc. (NASDAQ:TGTX) traded up 6.7% on Wednesday . The stock traded as high as $6.24 and last traded at $6.24, with a volume of 156,931 shares changing hands. The stock had previously closed at $5.85.

Several equities research analysts have weighed in on the stock. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Wednesday, May 4th. Brean Capital reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, June 7th. Roth Capital reaffirmed a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a research note on Thursday, June 9th. Zacks Investment Research downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. Finally, SunTrust Banks Inc. assumed coverage on shares of TG Therapeutics in a research note on Friday, May 27th. They issued a “buy” rating and a $18.00 price target for the company. One analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $22.33.

The stock’s 50-day moving average price is $6.33 and its 200 day moving average price is $8.04. The firm’s market capitalization is $335.64 million.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.08. On average, equities analysts anticipate that TG Therapeutics Inc. will post ($1.15) EPS for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund raised its stake in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent quarter.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.